|
|
|
|
|
06.03.26 - 09:30
|
Pfizers Weight Loss Injection GLP-1 Ecnoglutide Injection Approved in CN (AAStocks)
|
|
|
Pfizer China announced that the National Medical Products Administration (NMPA) has officially approved the new-generation cAMP-biased GLP-1 receptor agonist, ecnoglutide injection (Xianweiying), for long-term weight management in overweight and obese adults, in conjunction with dietary control and increased physical activity.At......
|
|
|
|
|
|
|
|
|
|
|
03.03.26 - 13:54
|
Pfizer Aktie: GLP-1-Pipeline überzeugt - Upgrade auf BUY! (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von Argus Research:
Die Analysten von Argus haben die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) von "hold" auf "buy" hochgestuft und ein Kursziel von 35 USD ausgegeben.
Die Analysten hätten ihre positive Einschätzung insbesondere mit den jüngsten Ergänzungen der GLP-1-Pipeline sowie mit den "robusten" Programmen in den Bereichen Onkologie und Hämatologie begründet. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
02.03.26 - 13:03
|
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines. ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
